__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
This page, and the associated content, is suitable for Great Britain healthcare professionals only.
Watch webinars on demand
Below you can access recordings from educational webinars hosted by experts in the field of CML, organised by Novartis. As the site grows, we’ll be adding more content, so come back soon!
You will be required to register/log in to watch the following videos.
Click through to access exclusive videos from the SCEMBLIX Launch Event. Join national and international experts as they discuss unmet needs in CML, TKI sequencing, the ASCEMBL trial and patient case studies.
Current treatment options for CML are sufficient: A debate
In this webinar, Dr Guy Hannah and Dr Onima Chowdhury present opposing arguments and share patient case studies to highlight the pros and cons of current treatment options for patients with CML. Click play to view the highlights, or click watch, to view the full debate.
Sign up to speak to a Novartis representative and make sure you don’t miss the latest updates
SCEMBLIX is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors, and without a known T315I mutation.1
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
CML, chronic myeloid leukaemia; TKI, tyrosine kinase inhibitor.
Reference
- SCEMBLIX (asciminib) Summary of Product Characteristics 2022. (Accessed June 2023)